18:52 , Feb 22, 2019 |  BC Week In Review  |  Company News

Generic Suboxone products enter U.S. market

At least three companies have launched in the U.S. generic versions of opioid dependence drug Suboxone buprenorphine/naloxone sublingual film from Indivior plc (LSE:INDV). The generic Suboxone manufacturers include Alvogen Inc. (Pinebrook, N.J.), the Sandoz unit...
21:49 , Oct 5, 2017 |  BC Extra  |  Company News

EU approval for Synthon's generic Copaxone

Synthon B.V. (Nijmegen, the Netherlands) and partner Alvogen Inc. (Pine Brook, N.J.) said a 40 mg/mL formulation of Remurel glatiramer acetate, their generic version of Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), received...
23:57 , Oct 2, 2015 |  BC Extra  |  Company News

Management tracks

Bayer AG (Xetra:BAYN) promoted Habib Dable to president of its U.S. pharmaceuticals division, Bayer HealthCare Pharmaceuticals. Dable was global head of specialty medicine for Bayer HealthCare Phamaceuticals. Molecular diagnostics play Myriad Genetics Inc. (NASDAQ:MYGN) named...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Company News

Acino sales and marketing update

Acino launched a generic version of Exelon Patch rivastigmine from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) in the U.S. Exelon Patch, an acetylcholinesterase (AChE) inhibitor, is approved in the U.S. to treat mild to moderate...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

DreamPharma, Alvogen deal

Alvogen will acquire generics play DreamPharma for $187 million in cash. Alvogen said the deal, which is expected to close next quarter, adds a portfolio of over 100 products. Alvogen develops, manufactures and distributes generic,...
07:00 , Aug 11, 2014 |  BioCentury  |  Strategy

Profusion of exclusions

Express Scripts Holding Co. 's 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes...
08:00 , Mar 3, 2014 |  BioCentury  |  Regulation

Subbing biosimilars in France

France's new biosimilars law creates a framework for a restricted form of substitution of innovator biologics. But how the law will actually be implemented won't be finalized until a ministerial decree is published, which could...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

Alvogen, Celltrion, Hospira sales and marketing update

Alvogen launched Inflectra infliximab, a biosimilar of autoimmune drug Remicade infliximab, in Central and Eastern Europe. Alvogen will market Inflectra in Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland and Romania. Remicade is a chimeric mAb...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Pernix Therapeutics management update

Pernix Therapeutics Holdings Inc. (NASDAQ:PTX), The Woodlands, Texas   Business: Infectious   Hired: Doug Drysdale as CEO and chairman, formerly CEO of Alvogen Inc. ; he succeeds Mike Pearce, who resigned  ...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Alvogen, Lotus Pharmaceuticals Co. Ltd. deal

Lotus will issue to Alvogen up to 151 million shares of Lotus stock valued at about $200 million. Alvogen will hold about a 67% stake in Lotus, which will use the proceeds to acquire several...